Michael Selgrad1, Peter Malfertheiner. 1. Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University of Magdeburg, Germany.
Abstract
PURPOSE OF REVIEW: The article will give an overview on reasons for treatment failure and tries to show new concepts for Helicobacter pylori treatment. RECENT FINDINGS: Several new treatment options or modifications of already established regimens have been introduced to overcome treatment failure. Antibiotic resistance to H. pylori is the key factor for treatment failure. At the moment, standard triple therapy remains the primary choice in regions with proven low clarithromycin resistance rates. In areas with high clarithromycin resistance, four drug treatment regimens, including quadruple and sequential therapy, have proven the best results as first-line regimens. The options for second-line treatment regimens are manifold. Second-line treatment regimens need to be adapted accurately to local resistance rates. SUMMARY: Treatment of H. pylori infection is challenged by a dramatic fall in eradication rates all over the world. Newer regimens have been introduced including sequential, quadruple therapies and those regimens provide promising results, but the knowledge about local resistance rates remains the key to an effective therapy.
PURPOSE OF REVIEW: The article will give an overview on reasons for treatment failure and tries to show new concepts for Helicobacter pylori treatment. RECENT FINDINGS: Several new treatment options or modifications of already established regimens have been introduced to overcome treatment failure. Antibiotic resistance to H. pylori is the key factor for treatment failure. At the moment, standard triple therapy remains the primary choice in regions with proven low clarithromycin resistance rates. In areas with high clarithromycin resistance, four drug treatment regimens, including quadruple and sequential therapy, have proven the best results as first-line regimens. The options for second-line treatment regimens are manifold. Second-line treatment regimens need to be adapted accurately to local resistance rates. SUMMARY: Treatment of H. pylori infection is challenged by a dramatic fall in eradication rates all over the world. Newer regimens have been introduced including sequential, quadruple therapies and those regimens provide promising results, but the knowledge about local resistance rates remains the key to an effective therapy.
Authors: Michael Selgrad; Ina Tammer; Cosima Langner; Jan Bornschein; Julia Meißle; Arne Kandulski; Mariya Varbanova; Thomas Wex; Dirk Schlüter; Peter Malfertheiner Journal: World J Gastroenterol Date: 2014-11-21 Impact factor: 5.742
Authors: Simona Di Caro; Lucia Fini; Yayha Daoud; Fabio Grizzi; Antonio Gasbarrini; Antonino De Lorenzo; Laura Di Renzo; Sara McCartney; Stuart Bloom Journal: World J Gastroenterol Date: 2012-10-28 Impact factor: 5.742
Authors: Trevelyan R Menheniott; Louise O'Connor; Yok Teng Chionh; Jan Däbritz; Michelle Scurr; Benjamin N Rollo; Garrett Z Ng; Shelley Jacobs; Angelique Catubig; Bayzar Kurklu; Stephen Mercer; Toshinari Minamoto; David E Ong; Richard L Ferrero; James G Fox; Timothy C Wang; Philip Sutton; Louise M Judd; Andrew S Giraud Journal: J Clin Invest Date: 2016-03-14 Impact factor: 14.808
Authors: Giuliana Sereni; Francesco Azzolini; Lorenzo Camellini; Debora Formisano; Francesco Decembrino; Veronica Iori; Cristiana Tioli; Maurizio Cavina; Francesco Di Mario; Giuliano Bedogni; Romano Sassatelli Journal: World J Gastroenterol Date: 2012-09-07 Impact factor: 5.742
Authors: Rodrigo G Ducati; Rajesh K Harijan; Scott A Cameron; Peter C Tyler; Gary B Evans; Vern L Schramm Journal: ACS Chem Biol Date: 2018-10-19 Impact factor: 5.100
Authors: Shanzhi Wang; Scott A Cameron; Keith Clinch; Gary B Evans; Zhimeng Wu; Vern L Schramm; Peter C Tyler Journal: J Am Chem Soc Date: 2015-11-09 Impact factor: 15.419